Tecan posts 2025 net loss after $140 mln writedown, warns on margins

Tecan booked a CHF 139.5m non-cash impairment, driving a FY2025 net loss of CHF 110.7m versus a CHF 67.7m profit a year earlier and EPS swinging to a loss of CHF 8.74 from CHF 5.30. Full-year sales fell 5.5% to CHF 882.5m (down 1.6% in local currencies) and adjusted EBITDA fell to CHF 142.1m (margin 16.1% vs 17.6%), with FX and tariffs shaving ~200bps; order intake was CHF 900.9m (broadly flat). Management launched a 'Rewired' transformation, kept the dividend at CHF 3/share, guided 2026 sales growth in low single-digit local-currency terms and an adjusted EBITDA margin of 15.5–16.5%, and reiterated a medium-term CHF 1bn sales / 20% adj. EBITDA target for 2028.

Analysis

The strategic pivot away from in-house design toward leveraging an internal contract-manufacturing arm is a classic capital-allocation tectonic shift: it can lift near-term gross margin on manufactured SKUs but risks hollowing out proprietary product pipelines and weakening OEM customer stickiness over multiple years. Expect a bifurcated outcome where EBITDA margin volatility compresses with better manufacturing efficiency while top-line comps become more binary — dependent on whether key customers accept a third-party-design model or seek alternate vendors with retained design services.

Currency and tariff exposures act as an accelerant to headline volatility and will make short-term guidance noisy; these macro drags also amplify the value of any operational improvement because incremental margin gains compound against a weakened base. Asia funding weakness is a structural demand shock that lengthens the timeline for recovery in instrument replacement cycles — any rebound will likely be driven by private-sector and diagnostics demand clusters rather than broad public research budgets.

The consensus framing centers on the headline reset; what it underestimates is the optionality embedded in a leaner manufacturing footprint combined with improved cash-conversion mechanics. Execution milestones over the next 6–18 months — order momentum, customer retention among OEM partners, and demonstrable margin recovery absent FX help — are binary catalysts that can re-rate the stock sharply if achieved, but failure to retain design-dependent customers is an asymmetric downside catalyst that could unfold over 12–36 months.

Key Decisions for Investors

• Long-core equity (TECN) sized 3–5% of book with 12–18 month horizon: add on a 10–15% pullback. Hedge with 6–9 month puts (10–15% OTM) sized at 30% of position to cap downside while preserving upside; reward scenario: 30–50% upside if execution on ‘Rewired’ shows sequential margin and order improvements, risk scenario: 20–30% downside if OEM attrition accelerates.
• Directional options: buy Jan-2027 call spread (buy lower-strike, sell higher-strike) to express a multi-quarter operational recovery with defined capital. Risk is limited to premium paid; target 2.5–4x payoff if milestones (quarterly order inflection + visible margin beat) occur within 12–18 months.
• Pair trade to isolate idiosyncratic operational recovery: long TECN (3% weight) / short Sartorius (SRT3 or SART.DE, 2% weight) for 9–12 month trade. Thesis: TECN re-rating tied to re-acceleration in partner orders and margin recovery while Sartorius has higher exposure to persistent public-lab spend weakness. Stop-loss: cut pair if TECN underperforms peer basket by >15% in 60 days.
• Immediate treasury/FX action: dress new longs with a CHF hedge for 6–12 months (forwards or swaps) to neutralize reported-currency volatility; this reduces headline earnings noise and lets operational improvements drive alpha. Cost is modest versus the value of avoiding misleading headline volatility in near-term quarters.